The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer

Journal of Biomolecular Techniques

Volumn 19, Issue 3, 2008, Pages 217-224

  Willmore Payne, Carlynn ^a   Holden, Joseph A ^b   Wittwer, Carl T ^b   Layfield, Lester J ^b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

DNA melting analysis; EGFR activating mutations; Non small cell lung cancer; Unlabeled DNA probes

Indexed keywords

DNA; PRIMER DNA;

ADENOCARCINOMA; ARTICLE; BIOTECHNOLOGY; DNA PROBE; EXON; FEMALE; GENE DELETION; GENETIC PROCEDURES; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTO ONCOGENE; SENSITIVITY AND SPECIFICITY; STATISTICS; TRANSCRIPTION INITIATION;

ADENOCARCINOMA; BASE SEQUENCE; BIOTECHNOLOGY; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA PROBES; DNA, NEOPLASM; EXONS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MOLECULAR PROBE TECHNIQUES; MUTATION; SENSITIVITY AND SPECIFICITY; SEQUENCE DELETION; TRANSCRIPTIONAL ACTIVATION;

EID: 63449140187     PISSN: 15240215     EISSN: 19434731     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med 2007;7:77-84.
2. Gunby RH, Sala E, Tartari CJ, Puttini M, Gambacorti-Passerini C, Mologni L. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med Chem 2007;7:594-616.
3. Yatabe Y, Mitsudomi T. Epidermal growth factor receptor mutations in lung cancers. Pathol Int 2007;l57:233-244.
4. Yun CH, Boggon TJ, Li Y, et al. Structures of lung cancerderived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-227.
5. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
6. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
7. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
8. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: An evolving story. Annu Rev Med 2008;59:429-442.
9. Hann CL, Brahmer JR. Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when? Curr Treat Options Oncol 2007;8:28-37.
10. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol 2005;23:6838-6845.
11. Willmore-Payne C, Holden JA, Layfield LJ. Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: Correlation with gene copy number, protein expression, and hormone receptor expression. Hum Pathol 2006;37:755-763.
12. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 2006;12:7232-7241.
13. Irmer D, Funk JO, Blaukat A. EGFR kinase domain mutations-functional impact and relevance for lung cancer therapy. Oncogene 2007,26:5693-5701.
14. Zhou L, Myers AN, Vandersteen JG, Wang L, Wittwer CT. Closed-tube genotyping with unlabeled oligonucleotide probes and a saturating DNA dye. Clin Chem 2004;50:1328-1335.
15. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23:6829-6837.
16. Smith GD, Chadwick BE, Willmore-Payne C, Bentz JS. Detection of EGFR gene mutations in cytology specimens from patients with non-small cell lung cancer utilizing high-resolution melting amplicon analysis. J Clin Pathol 2008;61(4):487-493.
17. Takano T, Ohe Y, Tsuta K, et al. Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non- small cell lung cancer treated with gefitinib. Clin Cancer Res 2007;13:5385-5390.
18. Krypuy M, Newnham GM, Thomas DM, Conron M, Dobrovic A. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006;6:295
19. Holden JA, Willmore-Payne C, Coppola D, Garrett CR, Lay-field LJ. High-resolution melting amplicon analysis as a method to detect c-kit and platelet-derived growth factor receptor alpha activating mutations in gastrointestinal stromal tumors. Am J Clin Pathol 2007;128:230-238.